Craig Hallum Issues Positive Forecast for Xeris Biopharma (NASDAQ:XERS) Stock Price

Xeris Biopharma (NASDAQ:XERS - Free Report) had its price target lifted by Craig Hallum from $5.00 to $6.50 in a research note released on Friday, Marketbeat Ratings reports. They currently have a buy rating on the stock.

A number of other research analysts have also commented on the company. Piper Sandler reaffirmed a "neutral" rating and set a $4.00 price target (up previously from $3.00) on shares of Xeris Biopharma in a research report on Friday, March 7th. Jefferies Financial Group reissued a "buy" rating and issued a $6.00 target price (up previously from $4.00) on shares of Xeris Biopharma in a research report on Wednesday, January 29th. Finally, HC Wainwright restated a "buy" rating and issued a $8.00 price target (up previously from $6.60) on shares of Xeris Biopharma in a research note on Friday, March 7th. One investment analyst has rated the stock with a hold rating and five have given a buy rating to the stock. According to MarketBeat, Xeris Biopharma presently has an average rating of "Moderate Buy" and an average target price of $5.92.

Xeris Biopharma Stock Performance

Xeris Biopharma stock traded down $0.01 during midday trading on Friday, hitting $4.56. 2,559,176 shares of the company's stock were exchanged, compared to its average volume of 2,129,183. The company has a market cap of $679.81 million, a P/E ratio of -10.13 and a beta of 2.32. Xeris Biopharma has a 52-week low of $1.69 and a 52-week high of $4.68. The stock has a 50-day moving average price of $3.64 and a two-hundred day moving average price of $3.29.

Remove Ads

Institutional Trading of Xeris Biopharma

Several institutional investors have recently added to or reduced their stakes in the business. China Universal Asset Management Co. Ltd. boosted its stake in Xeris Biopharma by 10.3% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 31,611 shares of the company's stock valued at $107,000 after purchasing an additional 2,954 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in Xeris Biopharma by 4.5% in the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 80,388 shares of the company's stock worth $273,000 after purchasing an additional 3,447 shares during the period. GPS Wealth Strategies Group LLC raised its holdings in Xeris Biopharma by 6.2% in the 4th quarter. GPS Wealth Strategies Group LLC now owns 66,925 shares of the company's stock worth $227,000 after purchasing an additional 3,900 shares during the period. Janney Montgomery Scott LLC raised its holdings in Xeris Biopharma by 31.4% in the 4th quarter. Janney Montgomery Scott LLC now owns 23,000 shares of the company's stock worth $78,000 after purchasing an additional 5,500 shares during the period. Finally, Prudential Financial Inc. raised its holdings in Xeris Biopharma by 23.4% in the 4th quarter. Prudential Financial Inc. now owns 36,945 shares of the company's stock worth $125,000 after purchasing an additional 7,000 shares during the period. 42.75% of the stock is currently owned by hedge funds and other institutional investors.

Xeris Biopharma Company Profile

Xeris Biopharma Holdings, Inc, a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.